Albiges, L., Gurney, H. P., Atduev, V., Suárez, C., Climent Duran, M. A., Pook, D., . . . Lee, C. H. (2022). 1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). Annals of Oncology, 33, S1204-S1205. https://doi.org/10.1016/j.annonc.2022.07.1551
Albiges, L., Tannir, N. M., Burotto, M., McDermott, D., Plimack, E. R., Barthélémy, P., . . . Motzer, R. J. (2020). Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 5(6), e001079. https://doi.org/10.1136/esmoopen-2020-001079
Algaba, F., Arce, Y., López-Beltrán, A., Montironi, R., Mikuz, G., & Bono, A. V. (2005). Intraoperative frozen section diagnosis in urological oncology. European Urology, 47(2), 129-136. https://doi.org/10.1016/j.eururo.2004.08.010
Allaf, M., Kim, S. E., Harshman, L. C., McDermott, D. F., Master, V. A., Signoretti, S., . . . Haas, N. B. (2022). LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Annals of Oncology, 33(Supplement 7), S1432-S1433. https://doi.org/10.1016/j.annonc.2022.08.072
Amin, M. B., Edge, S. B., Greene, F. L., Byrd, R. B., Brookland, R. K., Washington, M. K., . . . Meyer, L. R. (red.). (2017). AJCC Cancer Staging Manual (8. utg.). New York: Springer.
Andrews, J. R., Atwell, T., Schmit, G., Lohse, C. M., Kurup, A. N., Weisbrod, A., . . . Thompson, R. H. (2019). Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. European Urology, 76(2), 244-251. https://doi.org/10.1016/j.eururo.2019.04.026
Aoyama, H., Tago, M., & Shirato, H. (2015). Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial. JAMA Oncology, 1(4), 457-464. https://doi.org/10.1001/jamaoncol.2015.1145
Appleman, L. J., Puligandla, M., Pal, S. K., Harris, W., Agarwal, N., Costello, B. A., . . . Carducci, M. A. (2019). Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). Journal of Clinical Oncology, 37(15_suppl), 4502. https://doi.org/10.1200/JCO.2019.37.15_suppl.4502
Armstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., . . . George, D. J. (2016). Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncology, 17(3), 378-388. https://doi.org/10.1016/s1470-2045(15)00515-x
Auvray, M., Auclin, E., Barthelemy, P., Bono, P., Kellokumpu-Lehtinen, P., Gross-Goupil, M., . . . Albiges, L. (2019). Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European Journal of Cancer, 108, 33-40. https://doi.org/10.1016/j.ejca.2018.11.031
Beisland, C., Guðbrandsdottir, G., Reisæter, L. A., Bostad, L., & Hjelle, K. M. (2016). A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World Journal of Urology, 34(8), 1087-1099. https://doi.org/10.1007/s00345-016-1796-4
Beisland, C., Gudbrandsdottir, G., Reisæter, L. A., Bostad, L., Wentzel-Larsen, T., & Hjelle, K. M. (2015a). Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma. Scandinavian Journal of Urology, 49(3), 205-210. https://doi.org/10.3109/21681805.2014.980844
Beisland, C., Medby, P. C., & Beisland, H. O. (2004). Presumed radically treated renal cell carcinoma--recurrence of the disease and prognostic factors for subsequent survival. Scandinavian Journal of Urology and Nephrology, 38(4), 299-305. https://doi.org/10.1080/00365590410028818
Beisland, E., Beisland, C., Hjelle, K. M., Bakke, A., Aarstad, A. K., & Aarstad, H. J. (2015b). Health-related quality of life, personality and choice of coping are related in renal cell carcinoma patients. Scandinavian Journal of Urology, 49(4), 282-289. https://doi.org/10.3109/21681805.2014.990051
Beitler, J. J., Makara, D., Silverman, P., & Lederman, G. (2004). Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. American Journal of Clinical Oncology, 27(6), 646-648. https://doi.org/10.1097/01.coc.0000145289.57705.07
Bex, A., Mulders, P., Jewett, M., Wagstaff, J., van Thienen, J. V., Blank, C. U., . . . Haanen, J. (2019). Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncology, 5(2), 164-170. https://doi.org/10.1001/jamaoncol.2018.5543
Bex, A., Uzzo, R., Karam, J. A., Master, V. A., Donskov, F., Suarez, C., . . . Pal, S. K. (2022). LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. Annals of Oncology, 33(Supplement 7), S1431-S1432. https://doi.org/10.1016/j.annonc.2022.08.071
Bhindi, B., Abel, E. J., Albiges, L., Bensalah, K., Boorjian, S. A., Daneshmand, S., . . . Bex, A. (2019). Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. European Urology, 75(1), 111-128. https://doi.org/10.1016/j.eururo.2018.09.016
Bissada, N. K., Yakout, H. H., Babanouri, A., Elsalamony, T., Fahmy, W., Gunham, M., . . . Chaudhary, U. B. (2003). Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology, 61(1), 89-92. https://doi.org/10.1016/s0090-4295(02)02119-2
Blom, J. H., van Poppel, H., Maréchal, J. M., Jacqmin, D., Schröder, F. H., de Prijck, L., & Sylvester, R. (2009). Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. European Urology, 55(1), 28-34. https://doi.org/10.1016/j.eururo.2008.09.052
Blute, M. L., Boorjian, S. A., Leibovich, B. C., Lohse, C. M., Frank, I., & Karnes, R. J. (2007). Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. Journal of Urology, 178(2), 440-445; discussion 444. https://doi.org/10.1016/j.juro.2007.03.121
Blute, M. L., Leibovich, B. C., Lohse, C. M., Cheville, J. C., & Zincke, H. (2004). The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU International, 94(1), 33-41. https://doi.org/10.1111/j.1464-410X.2004.04897.x
Borregales, L. D., Kim, D. Y., Staller, A. L., Qiao, W., Thomas, A. Z., Adibi, M., . . . Karam, J. A. (2016). Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology, 34(5), 237.e219-226. https://doi.org/10.1016/j.urolonc.2015.11.020
Breda, A., Finelli, A., Janetschek, G., Porpiglia, F., & Montorsi, F. (2009). Complications of laparoscopic surgery for renal masses: prevention, management, and comparison with the open experience. European Urology, 55(4), 836-850. https://doi.org/10.1016/j.eururo.2009.01.018
Brierley, J. D., Gospodarowicz, M. K., & Wittekind, C. (red.). (2017). TNM Classification of Malignant Tumours (8. utg.). Oxford, UK og Hoboken, NJ: Wiley-Blackwell.
Bui, T. O., Dao, V. T., Nguyen, V. T., Feugeas, J. P., Pamoukdjian, F., & Bousquet, G. (2022). Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. European Urology, 81(4), 349-361. https://doi.org/10.1016/j.eururo.2021.12.010
Campbell, S. C., Clark, P. E., Chang, S. S., Karam, J. A., Souter, L., & Uzzo, R. G. (2021a). Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. Journal of Urology, 206(2), 199-208. https://doi.org/10.1097/ju.0000000000001911
Campbell, S. C., Uzzo, R. G., Karam, J. A., Chang, S. S., Clark, P. E., & Souter, L. (2021b). Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. Journal of Urology, 206(2), 209-218. https://doi.org/10.1097/ju.0000000000001912
Cantisani, V., Bertolotto, M., Clevert, D. A., Correas, J. M., Drudi, F. M., Fischer, T., . . . Sidhu, P. S. (2021). EFSUMB 2020 Proposal for a Contrast-Enhanced Ultrasound-Adapted Bosniak Cyst Categorization - Position Statement. Ultraschall in der Medizin, 42(2), 154-166. https://doi.org/10.1055/a-1300-1727
Capitanio, U., Bensalah, K., Bex, A., Boorjian, S. A., Bray, F., Coleman, J., . . . Russo, P. (2019). Epidemiology of Renal Cell Carcinoma. European Urology, 75(1), 74-84. https://doi.org/10.1016/j.eururo.2018.08.036
Capitanio, U., Larcher, A., Cianflone, F., Trevisani, F., Nini, A., Mottrie, A., . . . Bertini, R. (2020). Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. European Urology Oncology, 3(2), 209-215. https://doi.org/10.1016/j.euo.2019.02.006
Carlo, M. I., Mukherjee, S., Mandelker, D., Vijai, J., Kemel, Y., Zhang, L., . . . Offit, K. (2018). Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 4(9), 1228-1235. https://doi.org/10.1001/jamaoncol.2018.1986
Chan, V. W., Abul, A., Osman, F. H., Ng, H. H., Wang, K., Yuan, Y., . . . Wah, T. M. (2022). Ablative therapies versus partial nephrectomy for small renal masses - A systematic review and meta-analysis. International Journal of Surgery (London, England), 97, 106194. https://doi.org/10.1016/j.ijsu.2021.106194
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994). Validation of a combined comorbidity index. Journal of Clinical Epidemiology, 47(11), 1245-1251. https://doi.org/10.1016/0895-4356(94)90129-5
Chen, K., Liu, Z., Li, Y., Zhao, X., Zhang, S., Liu, C., . . . Ma, L. (2022). Diagnosis and treatment strategies for intraoperative pulmonary embolism caused by renal tumor thrombus shedding. Journal of Cardiac Surgery, 37(11), 3973-3983. https://doi.org/10.1111/jocs.16874
Choi, J. E., You, J. H., Kim, D. K., Rha, K. H., & Lee, S. H. (2015). Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. European Urology, 67(5), 891-901. https://doi.org/10.1016/j.eururo.2014.12.028
Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., . . . Motzer, R. J. (2015). Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 373(19), 1814-1823. https://doi.org/10.1056/NEJMoa1510016
Choueiri, T. K., Heng, D. Y. C., Lee, J. L., Cancel, M., Verheijen, R. B., Mellemgaard, A., . . . Albiges, L. (2020). Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncology, 6(8), 1247-1255. https://doi.org/10.1001/jamaoncol.2020.2218
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., . . . Motzer, R. J. (2021a). Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 384(9), 829-841. https://doi.org/10.1056/NEJMoa2026982
Choueiri, T. K., Powles, T. B., Albiges, L., Burotto, M., Szczylik, C., Zurawski, B., . . . Motzer, R. J. (2022). LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Annals of Oncology, 33, S1430-S1431. https://doi.org/10.1016/j.annonc.2022.08.070
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Chang, Y. H., . . . Powles, T. (2021b). Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. New England Journal of Medicine, 385(8), 683-694. https://doi.org/10.1056/NEJMoa2106391
Chow, E., Zeng, L., Salvo, N., Dennis, K., Tsao, M., & Lutz, S. (2012). Update on the systematic review of palliative radiotherapy trials for bone metastases. Clinical Oncology (Royal College of Radiologists), 24(2), 112-124. https://doi.org/10.1016/j.clon.2011.11.004
Churilla, T. M., Ballman, K. V., Brown, P. D., Twohy, E. L., Jaeckle, K., Farace, E., . . . Asher, A. L. (2017). Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. International Journal of Radiation Oncology, Biology, Physics, 99(5), 1173-1178. https://doi.org/10.1016/j.ijrobp.2017.07.045
Corica, F. A., Iczkowski, K. A., Cheng, L., Zincke, H., Blute, M. L., Wendel, A., . . . Bostwick, D. G. (1999). Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup. Journal of Urology, 161(2), 408-411. https://doi.org/10.1016/s0022-5347(01)61903-7
Correa, R. J. M., Louie, A. V., Zaorsky, N. G., Lehrer, E. J., Ellis, R., Ponsky, L., . . . Siva, S. (2019). The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. European Urology Focus, 5(6), 958-969. https://doi.org/10.1016/j.euf.2019.06.002
Dabestani, S., Beisland, C., Stewart, G. D., Bensalah, K., Gudmundsson, E., Lam, T. B., . . . Bex, A. (2019). Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scandinavian Journal of Urology, 53(1), 14-20. https://doi.org/10.1080/21681805.2019.1588919
Dabestani, S., Marconi, L., Hofmann, F., Stewart, F., Lam, T. B., Canfield, S. E., . . . Bex, A. (2014). Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncology, 15(12), e549-561. https://doi.org/10.1016/s1470-2045(14)70235-9
Dabestani, S., Thorstenson, A., Lindblad, P., Harmenberg, U., Ljungberg, B., & Lundstam, S. (2016). Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World Journal of Urology, 34(8), 1081-1086. https://doi.org/10.1007/s00345-016-1773-y
Delahunt, B., Cheville, J. C., Martignoni, G., Humphrey, P. A., Magi-Galluzzi, C., McKenney, J., . . . Srigley, J. R. (2013). The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. American Journal of Surgical Pathology, 37(10), 1490-1504. https://doi.org/10.1097/PAS.0b013e318299f0fb
Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., . . . Horwich, A. (2019). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 30(5), 706-720. https://doi.org/10.1093/annonc/mdz056
Ficarra, V., Novara, G., Secco, S., Macchi, V., Porzionato, A., De Caro, R., & Artibani, W. (2009). Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. European Urology, 56(5), 786-793. https://doi.org/10.1016/j.eururo.2009.07.040
Finelli, A., Cheung, D. C., Al-Matar, A., Evans, A. J., Morash, C. G., Pautler, S. E., . . . Jewett, M. A. S. (2020). Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. European Urology, 78(3), 460-467. https://doi.org/10.1016/j.eururo.2020.06.053
Finelli, A., Ismaila, N., Bro, B., Durack, J., Eggener, S., Evans, A., . . . Russo, P. (2017). Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 35(6), 668-680. https://doi.org/10.1200/jco.2016.69.9645
Flanigan, R. C., Mickisch, G., Sylvester, R., Tangen, C., Van Poppel, H., & Crawford, E. D. (2004). Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. Journal of Urology, 171(3), 1071-1076. https://doi.org/10.1097/01.ju.0000110610.61545.ae
Gershman, B., Thompson, R. H., Boorjian, S. A., Larcher, A., Capitanio, U., Montorsi, F., . . . Leibovich, B. C. (2018). Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. Journal of Urology, 199(5), 1143-1148. https://doi.org/10.1016/j.juro.2017.11.114
Gorin, M. A., Rowe, S. P., Baras, A. S., Solnes, L. B., Ball, M. W., Pierorazio, P. M., . . . Allaf, M. E. (2016). Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. European Urology, 69(3), 413-416. https://doi.org/10.1016/j.eururo.2015.08.056
Graham, J., Wells, J. C., Donskov, F., Lee, J. L., Fraccon, A., Pasini, F., . . . Heng, D. Y. C. (2019). Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2(6), 643-648. https://doi.org/10.1016/j.euo.2019.03.007
Gratzke, C., Seitz, M., Bayrle, F., Schlenker, B., Bastian, P. J., Haseke, N., . . . Bachmann, A. (2009). Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. BJU International, 104(4), 470-475. https://doi.org/10.1111/j.1464-410X.2009.08439.x
Gudbjartsson, T., Jónasdóttir, T. J., Thoroddsen, A., Einarsson, G. V., Jónsdóttir, G. M., Kristjánsson, K., . . . Amundadóttir, L. T. (2002). A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. International Journal of Cancer, 100(4), 476-479. https://doi.org/10.1002/ijc.10513
Hemal, A. K., Kumar, A., Kumar, R., Wadhwa, P., Seth, A., & Gupta, N. P. (2007). Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. Journal of Urology, 177(3), 862-866. https://doi.org/10.1016/j.juro.2006.10.053
Heng, D., Choueiri, T., & Xie, W. ([s.a.]). IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma. [nettressurs]. [s.l.]: MDCalc. Hentet 06. oktober 2022, fra https://www.mdcalc.com/calc/3008/imdc-international-metastatic-rcc-database-consortium-risk-model-metastatic-renal-cell-carcinoma
Heng, D. Y., Wells, J. C., Rini, B. I., Beuselinck, B., Lee, J. L., Knox, J. J., . . . Choueiri, T. K. (2014). Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 66(4), 704-710. https://doi.org/10.1016/j.eururo.2014.05.034
Heng, D. Y., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., . . . Choueiri, T. K. (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Journal of Clinical Oncology, 27(34), 5794-5799. https://doi.org/10.1200/jco.2008.21.4809
Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., . . . Yeh, H. (2011). Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology, 29(9), 1125-1132. https://doi.org/10.1200/jco.2010.31.3304
Hjelle, K. M., Johannesen, T. B., & Beisland, C. (2017). Postoperative 30-day Mortality Rates for Kidney Cancer Are Dependent on Hospital Surgical Volume: Results from a Norwegian Population-based Study. European Urology Focus, 3(2-3), 300-307. https://doi.org/10.1016/j.euf.2016.10.001
Hoskin, P. J., Hopkins, K., Misra, V., Holt, T., McMenemin, R., Dubois, D., . . . Lopes, A. (2019). Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial. JAMA, 322(21), 2084-2094. https://doi.org/10.1001/jama.2019.17913
Huang, D. Y., Yusuf, G. T., Daneshi, M., Husainy, M. A., Ramnarine, R., Sellars, M. E., & Sidhu, P. S. (2017). Contrast-enhanced US-guided Interventions: Improving Success Rate and Avoiding Complications Using US Contrast Agents. Radiographics, 37(2), 652-664. https://doi.org/10.1148/rg.2017160123
Huang, W. C., Donin, N. M., Levey, A. S., & Campbell, S. C. (2020). Chronic Kidney Disease and Kidney Cancer Surgery: New Perspectives. Journal of Urology, 203(3), 475-485. https://doi.org/10.1097/ju.0000000000000326
Huang, W. C., Elkin, E. B., Levey, A. S., Jang, T. L., & Russo, P. (2009). Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? Journal of Urology, 181(1), 55-61; discussion 61-52. https://doi.org/10.1016/j.juro.2008.09.017
Huang, W. C., Levey, A. S., Serio, A. M., Snyder, M., Vickers, A. J., Raj, G. V., . . . Russo, P. (2006). Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncology, 7(9), 735-740. https://doi.org/10.1016/s1470-2045(06)70803-8
Hunter, G. K., Balagamwala, E. H., Koyfman, S. A., Bledsoe, T., Sheplan, L. J., Reddy, C. A., . . . Videtic, G. M. M. (2012). The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Practical Radiation Oncology, 2(4), e95-e100. https://doi.org/10.1016/j.prro.2012.01.005
Hutson, T. E., Michaelson, M. D., Kuzel, T. M., Agarwal, N., Molina, A. M., Hsieh, J. J., . . . Fishman, M. N. (2021). A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. European Urology, 80(2), 162-170. https://doi.org/10.1016/j.eururo.2021.03.015
Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., . . . DiPaola, R. S. (2016). Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet, 387(10032), 2008-2016. https://doi.org/10.1016/s0140-6736(16)00559-6
Ingrosso, G., Becherini, C., Francolini, G., Lancia, A., Alì, E., Caini, S., . . . Detti, B. (2021). Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review. Critical Reviews in Oncology/Hematology, 159, 103242. https://doi.org/10.1016/j.critrevonc.2021.103242
Jeong, I. G., Khandwala, Y. S., Kim, J. H., Han, D. H., Li, S., Wang, Y., . . . Chung, B. I. (2017). Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy With Perioperative Outcomes and Health Care Costs, 2003 to 2015. JAMA, 318(16), 1561-1568. https://doi.org/10.1001/jama.2017.14586
Jhaveri, K., Gupta, P., Elmi, A., Flor, L., Moshonov, H., Evans, A., & Jewett, M. (2013). Cystic renal cell carcinomas: do they grow, metastasize, or recur? AJR: American Journal of Roentgenology, 201(2), W292-296. https://doi.org/10.2214/ajr.12.9414
Johnson, D. C., Vukina, J., Smith, A. B., Meyer, A. M., Wheeler, S. B., Kuo, T. M., . . . Nielsen, M. E. (2015). Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. Journal of Urology, 193(1), 30-35. https://doi.org/10.1016/j.juro.2014.07.102
Kanesvaran, R., Le Saux, O., Motzer, R., Choueiri, T. K., Scotté, F., Bellmunt, J., & Launay-Vacher, V. (2018). Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncology, 19(6), e317-e326. https://doi.org/10.1016/s1470-2045(18)30125-6
Karellas, M. E., Jang, T. L., Kagiwada, M. A., Kinnaman, M. D., Jarnagin, W. R., & Russo, P. (2009). Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection. BJU International, 103(2), 160-164. https://doi.org/10.1111/j.1464-410X.2008.08025.x
Karnofsky score for performance status calculator. (24. Januar 2016). [nettressurs]. [s.l.]: Thecalculator.co. Hentet 03. oktober 2022, fra https://www.thecalculator.co/health/Karnofsky-Score-for-Performance-Status-Calculator-961.html
Khoo, V. S., & Pyle, L. (2007). Radiotherapy and supportive care. I: T. Eisen & T. Christmas (red.), Clinical Progress in Renal Cancer (s. 191–201). Oxford: Informa UK Ltd,.
Klatte, T., Rossi, S. H., & Stewart, G. D. (2018). Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World Journal of Urology, 36(12), 1943-1952. https://doi.org/10.1007/s00345-018-2309-4
Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., . . . Motzer, R. J. (2017). Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology, 28(6), 1339-1345. https://doi.org/10.1093/annonc/mdx075
Ko, J. J., Xie, W., Kroeger, N., Lee, J. L., Rini, B. I., Knox, J. J., . . . Heng, D. Y. (2015). The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncology, 16(3), 293-300. https://doi.org/10.1016/s1470-2045(14)71222-7
Kunkle, D. A., Egleston, B. L., & Uzzo, R. G. (2008). Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. Journal of Urology, 179(4), 1227-1233; discussion 1233-1224. https://doi.org/10.1016/j.juro.2007.11.047
Kutikov, A., & Uzzo, R. G. (2009). The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. Journal of Urology, 182(3), 844-853. https://doi.org/10.1016/j.juro.2009.05.035
Laird, A., Choy, K. C., Delaney, H., Cutress, M. L., O'Connor, K. M., Tolley, D. A., . . . Riddick, A. C. (2015). Matched pair analysis of laparoscopic versus open radical nephrectomy for the treatment of T3 renal cell carcinoma. World Journal of Urology, 33(1), 25-32. https://doi.org/10.1007/s00345-014-1280-y
Lane, B. R., Abouassaly, R., Gao, T., Weight, C. J., Hernandez, A. V., Larson, B. T., . . . Campbell, S. C. (2010). Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer, 116(13), 3119-3126. https://doi.org/10.1002/cncr.25184
Lane, B. R., Tiong, H. Y., Campbell, S. C., Fergany, A. F., Weight, C. J., Larson, B. T., . . . Flechner, S. M. (2009). Management of the adrenal gland during partial nephrectomy. Journal of Urology, 181(6), 2430-2436; discussion 2436-2437. https://doi.org/10.1016/j.juro.2009.02.027
Lardas, M., Stewart, F., Scrimgeour, D., Hofmann, F., Marconi, L., Dabestani, S., . . . Lam, T. B. (2016). Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. European Urology, 70(2), 265-280. https://doi.org/10.1016/j.eururo.2015.11.034
Larsen, I. K. (red.). (2022). Cancer in Norway 2021 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/globalassets/cancer-in-norway/2021/cin_report.pdf
Lee, C. H., Shah, A. Y., Rasco, D., Rao, A., Taylor, M. H., Di Simone, C., . . . Motzer, R. J. (2021). Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncology, 22(7), 946-958. https://doi.org/10.1016/s1470-2045(21)00241-2
Lee, C. H., Voss, M. H., Carlo, M. I., Chen, Y. B., Zucker, M., Knezevic, A., . . . Motzer, R. J. (2022). Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. Journal of Clinical Oncology, 40(21), 2333-2341. https://doi.org/10.1200/jco.21.01944
Lee, J., Hodgson, D., Chow, E., Bezjak, A., Catton, P., Tsuji, D., . . . Gospodarowicz, M. K. (2005). A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer, 104(9), 1894-1900. https://doi.org/10.1002/cncr.21410
Leibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., . . . Zincke, H. (2003). Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer, 97(7), 1663-1671. https://doi.org/10.1002/cncr.11234
Leibovich, B. C., Lohse, C. M., Cheville, J. C., Zaid, H. B., Boorjian, S. A., Frank, I., . . . Parker, W. P. (2018). Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. European Urology, 73(5), 772-780. https://doi.org/10.1016/j.eururo.2018.01.005
Liu, H., Kong, Q. F., Li, J., Wu, Y. Q., Pan, K. H., Xu, B., . . . Chen, M. (2021). A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma. Translational andrology and urology, 10(3), 1170-1178. https://doi.org/10.21037/tau-20-1262
Liu, Z., Zhang, L., Hong, P., Li, L., Tang, S., Zhao, X., . . . Ma, L. (2020). The influence of venous tumor thrombus combined with bland thrombus on the surgical treatment and prognosis of renal cell carcinoma patients. Cancer medicine, 9(16), 5860-5868. https://doi.org/10.1002/cam4.3264
Ljungberg, B., Alamdari, F. I., Rasmuson, T., & Roos, G. (1999). Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU International, 84(4), 405-411. https://doi.org/10.1046/j.1464-410x.1999.00202.x
Ljungberg, B., Albiges, L., Abu-Ghanem, Y., Bedke, J., Capitanio, U., Dabestani, S., . . . Bex, A. (2022a). European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. European Urology, 82(4), 399-410. https://doi.org/10.1016/j.eururo.2022.03.006
Ljungberg, B., Albiges, L., Bedke, J., Bex, A., Capitanio, U., Giles, R. H., . . . Volpe, A. (2022b). 5.2.3. Other investigations. I: Renal Cell Carcinoma. Arnhem: EAU. Hentet fra https://uroweb.org/guidelines/renal-cell-carcinoma
Ljungberg, B., Albiges, L., Bedke, J., Bex, A., Capitanio, U., Giles, R. H., . . . Volpe, A. (2022c). Renal Cell Carcinoma. Arnhem: EAU. Hentet fra https://uroweb.org/guidelines/renal-cell-carcinoma
Ljungberg, B., Sundqvist, P., Lindblad, P., Kjellman, A., Thorstenson, A., Hellström, M., . . . Lundstam, S. (2020). Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. Scandinavian Journal of Urology, 54(6), 487-492. https://doi.org/10.1080/21681805.2020.1815833
Loft, A., Hesse, B., & Birk Christensen, C. (2011). Klinisk nuklearmedicin (2. utg.). [s.l.]: Dansk selskab for klinisk fysiologi og nuklearmedicin.
Lui, S. T., & Shuch, B. (2019). Genetic Testing in Kidney Cancer Patients: Who, When, and How? European Urology Focus, 5(6), 973-976. https://doi.org/10.1016/j.euf.2019.09.005
Macklin, P. S., Sullivan, M. E., Tapping, C. R., Cranston, D. W., Webster, G. M., Roberts, I. S. D., . . . Browning, L. (2019). Tumour Seeding in the Tract of Percutaneous Renal Tumour Biopsy: A Report on Seven Cases from a UK Tertiary Referral Centre. European Urology, 75(5), 861-867. https://doi.org/10.1016/j.eururo.2018.12.011
MacLennan, S., Imamura, M., Lapitan, M. C., Omar, M. I., Lam, T. B., Hilvano-Cabungcal, A. M., . . . N'Dow, J. (2012). Systematic review of oncological outcomes following surgical management of localised renal cancer. European Urology, 61(5), 972-993. https://doi.org/10.1016/j.eururo.2012.02.039
Marconi, L., Dabestani, S., Lam, T. B., Hofmann, F., Stewart, F., Norrie, J., . . . Volpe, A. (2016). Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. European Urology, 69(4), 660-673. https://doi.org/10.1016/j.eururo.2015.07.072
Margulis, V., Sánchez-Ortiz, R. F., Tamboli, P., Cohen, D. D., Swanson, D. A., & Wood, C. G. (2007). Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer, 109(10), 2025-2030. https://doi.org/10.1002/cncr.22629
Mason, R. J., Abdolell, M., Trottier, G., Pringle, C., Lawen, J. G., Bell, D. G., . . . Rendon, R. A. (2011). Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. European Urology, 59(5), 863-867. https://doi.org/10.1016/j.eururo.2011.02.023
McDermott, D. F., Lee, J. L., Ziobro, M., Suarez, C., Langiewicz, P., Matveev, V. B., . . . Atkins, M. B. (2021). Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 39(9), 1029-1039. https://doi.org/10.1200/jco.20.02365
McNichols, D. W., Segura, J. W., & DeWeerd, J. H. (1981). Renal cell carcinoma: long-term survival and late recurrence. Journal of Urology, 126(1), 17-23. https://doi.org/10.1016/s0022-5347(17)54359-1
Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J. B., Bensalah, K., . . . Escudier, B. (2018). Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 379(5), 417-427. https://doi.org/10.1056/NEJMoa1803675
Menko, F. H., van Steensel, M. A., Giraud, S., Friis-Hansen, L., Richard, S., Ungari, S., . . . Maher, E. R. (2009). Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncology, 10(12), 1199-1206. https://doi.org/10.1016/s1470-2045(09)70188-3
Mir, M. C., Derweesh, I., Porpiglia, F., Zargar, H., Mottrie, A., & Autorino, R. (2017). Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. European Urology, 71(4), 606-617. https://doi.org/10.1016/j.eururo.2016.08.060
Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016). The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. European Urology, 70(1), 93-105. https://doi.org/10.1016/j.eururo.2016.02.029
Motzer, R., Alekseev, B., Rha, S. Y., Porta, C., Eto, M., Powles, T., . . . Choueiri, T. K. (2021a). Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 384(14), 1289-1300. https://doi.org/10.1056/NEJMoa2035716
Motzer, R. J., Escudier, B., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., . . . Tannir, N. M. (2020). Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer, 126(18), 4156-4167. https://doi.org/10.1002/cncr.33033
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., . . . Sharma, P. (2015a). Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 373(19), 1803-1813. https://doi.org/10.1056/NEJMoa1510665
Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., . . . Larkin, J. (2015b). Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncology, 16(15), 1473-1482. https://doi.org/10.1016/s1470-2045(15)00290-9
Motzer, R. J., Haas, N. B., Donskov, F., Gross-Goupil, M., Varlamov, S., Kopyltsov, E., . . . Sternberg, C. N. (2017). Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 35(35), 3916-3923. https://doi.org/10.1200/jco.2017.73.5324
Motzer, R. J., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Shah, A. Y., . . . Choueiri, T. K. (2022a). Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncology, 23(7), 888-898. https://doi.org/10.1016/s1470-2045(22)00290-x
Motzer, R. J., Russo, P., Gruenwald, V., Tomita, Y., Zurawski, B., Parikh, O. A., . . . Bex, A. (2022b). LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial. Annals of Oncology, 33(Supplement 7), S1430. https://doi.org/10.1016/j.annonc.2022.08.069
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., . . . Escudier, B. (2018). Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 378(14), 1277-1290. https://doi.org/10.1056/NEJMoa1712126
Motzer, R. J., Tannir, N. M., McDermott, D. F., Burotto, M., Choueiri, T. K., Hammers, H. J., . . . Escudier, B. (2021b). 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Annals of Oncology, 32(Suppl_5), S685-S687. https://doi.org/10.1016/j.annonc.2021.08.057
Mucci, L. A., Hjelmborg, J. B., Harris, J. R., Czene, K., Havelick, D. J., Scheike, T., . . . Collaboration, f. t. N. T. S. o. C. (2016). Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA, 315(1), 68-76. https://doi.org/10.1001/jama.2015.17703
Mulvenna, P., Nankivell, M., Barton, R., Faivre-Finn, C., Wilson, P., McColl, E., . . . Langley, R. E. (2016). Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet, 388(10055), 2004-2014. https://doi.org/10.1016/s0140-6736(16)30825-x
NCCN. (2013). PET PROS: PET professional resourves and outreach score: Part I: NCCN Practice Guidelines Tabular Summary (DD 3/20/13). Plymouth Meeting: NCCN. Hentet fra http://s3.amazonaws.com/rdcms-snmmi/files/production/public/docs/PET_PROS/NCCNPracticeGuidelinesI.pdf
Nguyen, K. A., Syed, J. S., Espenschied, C. R., LaDuca, H., Bhagat, A. M., Suarez-Sarmiento, A., . . . Shuch, B. (2017). Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test. Cancer, 123(22), 4363-4371. https://doi.org/10.1002/cncr.30893
Northrup, H., Aronow, M. E., Bebin, E. M., Bissler, J., Darling, T. N., de Vries, P. J., . . . Krueger, D. A. (2021). Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 123, 50-66. https://doi.org/10.1016/j.pediatrneurol.2021.07.011
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5(6), 649-655.
Olsen, T. K. (18. januar 2019). Målrettet kreftbehandling. Store medisinske leksikon [nettdokument]. Oslo: Store norske leksikon. Hentet 06. oktober 2022, fra https://sml.snl.no/m%C3%A5lrettet_kreftbehandling
Olson, J. J., Kalkanis, S. N., & Ryken, T. C. (2019). Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Treatment of Adults With Metastatic Brain Tumors: Executive Summary. Neurosurgery, 84(3), 550-552. https://doi.org/10.1093/neuros/nyy540
Ornstein, M. C., Pal, S. K., Wood, L. S., Tomer, J. M., Hobbs, B. P., Jia, X. S., . . . Rini, B. I. (2019). Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncology, 20(10), 1386-1394. https://doi.org/10.1016/s1470-2045(19)30513-3
Osterman, C. K., Deal, A. M., Milowsky, M. I., Bjurlin, M. A., & Rose, T. L. (2020). Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma. Kidney Cancer, 4(3), 131-137. https://doi.org/10.3233/kca-200089
Pal, S. K., Tangen, C., Thompson, I. M., Jr., Balzer-Haas, N., George, D. J., Heng, D. Y. C., . . . Lara, P. N., Jr. (2021). A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet, 397(10275), 695-703. https://doi.org/10.1016/s0140-6736(21)00152-5
Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., . . . Young, B. (2005). Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet, 366(9486), 643-648. https://doi.org/10.1016/s0140-6736(05)66954-1
Patel, H. D., Druskin, S. C., Rowe, S. P., Pierorazio, P. M., Gorin, M. A., & Allaf, M. E. (2017). Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU International, 119(5), 661-666. https://doi.org/10.1111/bju.13763
Patel, N., Cranston, D., Akhtar, M. Z., George, C., Jones, A., Leiblich, A., . . . Sullivan, M. (2012). Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU International, 110(9), 1270-1275. https://doi.org/10.1111/j.1464-410X.2012.11130.x
PDQ Cancer Genetics Editorial Board. (2002). Birt-Hogg-Dubé Syndrome (PDQ®): Health Professional Version. I: PDQ Cancer Information Summaries. [nettdokument]. Bethesda (MD): National Cancer Institute (US). Hentet 06. oktober 2022, fra https://www.ncbi.nlm.nih.gov/books/NBK568510/
Pedrosa, I., Sun, M. R., Spencer, M., Genega, E. M., Olumi, A. F., Dewolf, W. C., & Rofsky, N. M. (2008). MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics, 28(4), 985-1003. https://doi.org/10.1148/rg.284065018
Peyronnet, B., Tondut, L., Bernhard, J. C., Vaessen, C., Doumerc, N., Sebe, P., . . . Bensalah, K. (2018). Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy outcomes: a multicentre study. BJU International, 121(6), 916-922. https://doi.org/10.1111/bju.14175
Pierorazio, P., McKiernan, J., & Allaf, M. (2013). 633 Quality of life on active surveillance for small masses versus immediate intervention: interim analysis of the DISSRM (delayed intervention and surveillance for small renal masses) registry. Journal of Urology, 189(4S), e259. https://doi.org/10.1016/j.juro.2013.02.185
Pierorazio, P. M., Johnson, M. H., Ball, M. W., Gorin, M. A., Trock, B. J., Chang, P., . . . Allaf, M. E. (2015). Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. European Urology, 68(3), 408-415. https://doi.org/10.1016/j.eururo.2015.02.001
Pierorazio, P. M., Johnson, M. H., Patel, H. D., Sozio, S. M., Sharma, R., Iyoha, E., . . . Allaf, M. E. (2016). Management of Renal Masses and Localized Renal Cancer: Comparative Effectiveness Review No. 167 (AHRQ Publication No.: 16-EHC001-EF). Rockville (MD): Agency for Healthcare Research and Quality (US). Hentet fra https://www.ncbi.nlm.nih.gov/books/NBK350333/
Pillay, B., Wootten, A. C., Crowe, H., Corcoran, N., Tran, B., Bowden, P., . . . Costello, A. J. (2016). The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews, 42, 56-72. https://doi.org/10.1016/j.ctrv.2015.11.007
Porta, C. G., Eto, M., Motzer, R. J., De Giorgi, U. F. F., Buchler, T., Basappa, N. S., . . . Choueiri, T. K. (2022). 1449MO Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study. Annals of Oncology, 33(Supplement 7), S1205-S1206. https://doi.org/10.1016/j.annonc.2022.07.1552
Powles, T., Albiges, L., Bex, A., Grünwald, V., Porta, C., Procopio, G., . . . de Velasco, G. (2021). ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Annals of Oncology, 32(12), 1511-1519. https://doi.org/10.1016/j.annonc.2021.09.014
Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., . . . Rini, B. I. (2020). Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncology, 21(12), 1563-1573. https://doi.org/10.1016/s1470-2045(20)30436-8
Procopio, G., Apollonio, G., Cognetti, F., Miceli, R., Milella, M., Mosca, A., . . . Verzoni, E. (2019). Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. European Urology Oncology, 2(6), 699-707. https://doi.org/10.1016/j.euo.2019.08.011
Putra, L. G., Minor, T. X., Bolton, D. M., Appu, S., Dowling, C. R., & Neerhut, G. J. (2009). Improved assessment of renal lesions in pregnancy with magnetic resonance imaging. Urology, 74(3), 535-539. https://doi.org/10.1016/j.urology.2008.07.050
Quivy, A., Daste, A., Harbaoui, A., Duc, S., Bernhard, J. C., Gross-Goupil, M., & Ravaud, A. (2013). Optimal management of renal cell carcinoma in the elderly: a review. Clinical Interventions in Aging, 8, 433-442. https://doi.org/10.2147/cia.S30765
Rades, D., Conde-Moreno, A. J., Cacicedo, J., Šegedin, B., Stanic, K., Metz, M., . . . Schild, S. E. (2018). Comparison of Two Radiotherapy Regimens for Metastatic Spinal Cord Compression: Subgroup Analyses from a Randomized Trial. Anticancer Research, 38(2), 1009-1015. https://doi.org/10.21873/anticanres.12316
Ravaud, A., Motzer, R. J., Pandha, H. S., George, D. J., Pantuck, A. J., Patel, A., . . . Patard, J. J. (2016). Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. New England Journal of Medicine, 375(23), 2246-2254. https://doi.org/10.1056/NEJMoa1611406
Regionalt cancercentrum. (2019). Njurcancer: nationellt vårdprogram (rev. utg.). Stockholm: Regionala cancercentrum i samverkan.
Regionalt cancercentrum. (2022a). Nationella kvalitetsregistret för njurcancer [nettdokument]. Stockholm: Regionala cancercentrum i samverkan. Hentet fra https://cancercentrum.se/samverkan/cancerdiagnoser/njure/kvalitetsregister/
Regionalt cancercentrum. (2022b). Njurcancer: nationellt vårdprogram. (Version: 5.1.). Stockholm: Regionala cancercentrum i samverkan. Hentet fra https://cancercentrum.se/samverkan/cancerdiagnoser/njure/vardprogram/
Reichel, L. M., Pohar, S., Heiner, J., Buzaianu, E. M., & Damron, T. A. (2007). Radiotherapy to bone has utility in multifocal metastatic renal carcinoma. Clinical Orthopaedics and Related Research, 459, 133-138. https://doi.org/10.1097/BLO.0b013e3180616594
Riazalhosseini, Y., & Lathrop, M. (2016). Precision medicine from the renal cancer genome. Nat Rev Nephrol, 12(11), 655-666. https://doi.org/10.1038/nrneph.2016.133
Rich, S. E., Chow, R., Raman, S., Liang Zeng, K., Lutz, S., Lam, H., . . . Chow, E. (2018). Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiotherapy and Oncology, 126(3), 547-557. https://doi.org/10.1016/j.radonc.2018.01.003
Richard, P. O., Violette, P. D., Bhindi, B., Breau, R. H., Kassouf, W., Lavallée, L. T., . . . Nayak, J. (2022). Canadian Urological Association guideline: Management of small renal masses - Full-text. Canadian Urological Association journal, 16(2), E61-e75. https://doi.org/10.5489/cuaj.7763
Rini, B. I., Pal, S. K., Escudier, B. J., Atkins, M. B., Hutson, T. E., Porta, C., . . . McDermott, D. F. (2020). Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncology, 21(1), 95-104. https://doi.org/10.1016/s1470-2045(19)30735-1
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., . . . Powles, T. (2019). Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 380(12), 1116-1127. https://doi.org/10.1056/NEJMoa1816714
Rodríguez-Fernández, I. A., Rodríguez-Romo, L., Hernandez-Barajas, D., Gonzalez-Conchas, G. A., Verdines-Perez, A., Templeton, A. J., . . . Vera-Badillo, F. E. (2019). Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. European Urology Oncology, 2(4), 448-455. https://doi.org/10.1016/j.euo.2018.10.003
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., . . . Seaman, J. (2004). Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer, 100(12), 2613-2621. https://doi.org/10.1002/cncr.20308
Ryan, C. W., Tangen, C., Heath, E. I., Stein, M. N., Meng, M., Alva, A. S., . . . Lara, P. L. N. (2022). EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249). Journal of Clinical Oncology, 40(17_suppl), LBA4500. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA4500
Schoots, I. G., Zaccai, K., Hunink, M. G., & Verhagen, P. (2017). Bosniak Classification for Complex Renal Cysts Reevaluated: A Systematic Review. Journal of Urology, 198(1), 12-21. https://doi.org/10.1016/j.juro.2016.09.160
Sebastià, C., Corominas, D., Musquera, M., Paño, B., Ajami, T., & Nicolau, C. (2020). Active surveillance of small renal masses. Insights Imaging, 11(1), 63. https://doi.org/10.1186/s13244-020-00853-y
Shah, A. Y., Karam, J. A., Malouf, G. G., Rao, P., Lim, Z. D., Jonasch, E., . . . Tannir, N. M. (2017). Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU International, 120(6), 782-792. https://doi.org/10.1111/bju.13705
Shirodkar, S. P., Ciancio, G., & Soloway, M. S. (2009). Words of wisdom. Re: Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. European Urology, 55(6), 1485-1486. https://doi.org/10.1016/j.eururo.2009.03.036
Shuch, B., Larochelle, J. C., Onyia, T., Vallera, C., Margulis, D., Pantuck, A. J., . . . Belldegrun, A. S. (2009). Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. Journal of Urology, 181(2), 492-498; discussion 498-499. https://doi.org/10.1016/j.juro.2008.10.036
Shuch, B., Vourganti, S., Ricketts, C. J., Middleton, L., Peterson, J., Merino, M. J., . . . Linehan, W. M. (2014). Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. Journal of Clinical Oncology, 32(5), 431-437. https://doi.org/10.1200/JCO.2013.50.8192
Silverman, S. G., Pedrosa, I., Ellis, J. H., Hindman, N. M., Schieda, N., Smith, A. D., . . . Davenport, M. S. (2019). Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology, 292(2), 475-488. https://doi.org/10.1148/radiol.2019182646
Siva, S., Pham, D., Kron, T., Bressel, M., Lam, J., Tan, T. H., . . . Foroudi, F. (2017). Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU International, 120(5), 623-630. https://doi.org/10.1111/bju.13811
Smaldone, M. C., Kutikov, A., Egleston, B. L., Canter, D. J., Viterbo, R., Chen, D. Y., . . . Uzzo, R. G. (2012). Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 118(4), 997-1006. https://doi.org/10.1002/cncr.26369
Soffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., . . . Weller, M. (2017). Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 19(2), 162-174. https://doi.org/10.1093/neuonc/now241
Soffietti, R., Kocher, M., Abacioglu, U. M., Villa, S., Fauchon, F., Baumert, B. G., . . . Bottomley, A. (2013). A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. Journal of Clinical Oncology, 31(1), 65-72. https://doi.org/10.1200/jco.2011.41.0639
Srigley, J. R., Delahunt, B., Eble, J. N., Egevad, L., Epstein, J. I., Grignon, D., . . . Argani, P. (2013). The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 37(10), 1469-1489. https://doi.org/10.1097/PAS.0b013e318299f2d1
Steinberg, A. P., Finelli, A., Desai, M. M., Abreu, S. C., Ramani, A. P., Spaliviero, M., . . . Gill, I. S. (2004). Laparoscopic radical nephrectomy for large (greater than 7 cm, T2) renal tumors. Journal of Urology, 172(6 Pt 1), 2172-2176. https://doi.org/10.1097/01.ju.0000140961.53335.04
Stenman, M., Sinclair, G., Paavola, P., Wersäll, P., Harmenberg, U., & Lindskog, M. (2018). Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. Radiotherapy and Oncology, 127(3), 501-506. https://doi.org/10.1016/j.radonc.2018.04.028
Stenzl, A., Witjes, J. A., Cowan, N. C., De Santis, M., Kuczyk, M., Lebret, T., . . . Sherif, A. (2011). Guidelines on bladder cancer, muscle-invasive and metastatic. Arnhem: European Association of Urology. Hentet fra https://d56bochluxqnz.cloudfront.net/documents/EAU-Guidelines-on-Muscle-invasive-and-Metastatic-Bladder-Cancer-2011.pdf
Stewart-Merrill, S. B., Thompson, R. H., Boorjian, S. A., Psutka, S. P., Lohse, C. M., Cheville, J. C., . . . Frank, I. (2015). Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. Journal of Clinical Oncology, 33(35), 4151-4157. https://doi.org/10.1200/jco.2015.61.8009
Sun, M., Bianchi, M., Trinh, Q. D., Abdollah, F., Schmitges, J., Jeldres, C., . . . Karakiewicz, P. I. (2012). Hospital volume is a determinant of postoperative complications, blood transfusion and length of stay after radical or partial nephrectomy. Journal of Urology, 187(2), 405-410. https://doi.org/10.1016/j.juro.2011.10.025
Sun, M., Marconi, L., Eisen, T., Escudier, B., Giles, R. H., Haas, N. B., . . . Bex, A. (2018). Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European Urology, 74(5), 611-620. https://doi.org/10.1016/j.eururo.2018.05.002
Svedman, C., Karlsson, K., Rutkowska, E., Sandström, P., Blomgren, H., Lax, I., & Wersall, P. (2008). Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncologica, 47(8), 1578-1583. https://doi.org/10.1080/02841860802123196
Svedman, C., Sandstrom, P., Pisa, P., Blomgren, H., Lax, I., Kalkner, K. M., . . . Wersall, P. (2006). A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncologica, 45(7), 870-875. https://doi.org/10.1080/02841860600954875
Tachibana, H., Kondo, T., Ishihara, H., Fukuda, H., Yoshida, K., Takagi, T., . . . Tanabe, K. (2021). Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. Japanese Journal of Clinical Oncology, 51(4), 646-653. https://doi.org/10.1093/jjco/hyaa229
Tahbaz, R., Schmid, M., & Merseburger, A. S. (2018). Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Current opinion in urology, 28(1), 62-79. https://doi.org/10.1097/mou.0000000000000454
Tannir, N. M., Jonasch, E., Albiges, L., Altinmakas, E., Ng, C. S., Matin, S. F., . . . Choueiri, T. K. (2016). Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. European Urology, 69(5), 866-874. https://doi.org/10.1016/j.eururo.2015.10.049
Tannir, N. M., Signoretti, S., Choueiri, T. K., McDermott, D. F., Motzer, R. J., Flaifel, A., . . . Rini, B. I. (2021). Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 27(1), 78-86. https://doi.org/10.1158/1078-0432.Ccr-20-2063
Testa, U., Pelosi, E., & Castelli, G. (2020). Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. Medicines (Basel), 7(8). https://doi.org/10.3390/medicines7080044
Tikkinen, K. A. O., Cartwright, R., Gould, M. K., Naspro, R., Novara, G., Sandset, P. M., . . . Guyatt, G. H. (2022). Thromboprophylaxis. Arnhem: EAU. Hentet fra https://uroweb.org/guidelines/thromboprophylaxis
Townsend, P. W., Smalley, S. R., Cozad, S. C., Rosenthal, H. G., & Hassanein, R. E. (1995). Role of postoperative radiation therapy after stabilization of fractures caused by metastatic disease. International Journal of Radiation Oncology, Biology, Physics, 31(1), 43-49. https://doi.org/10.1016/0360-3016(94)e0310-g
Trpkov, K., Grignon, D. J., Bonsib, S. M., Amin, M. B., Billis, A., Lopez-Beltran, A., . . . Srigley, J. R. (2013). Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. American Journal of Surgical Pathology, 37(10), 1505-1517. https://doi.org/10.1097/PAS.0b013e31829a85d0
Trpkov, K., Hes, O., Williamson, S. R., Adeniran, A. J., Agaimy, A., Alaghehbandan, R., . . . Gill, A. J. (2021). New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 34(7), 1392-1424. https://doi.org/10.1038/s41379-021-00779-w
Tse, J. R., Shen, J., Yoon, L., & Kamaya, A. (2020). Bosniak Classification Version 2019 of Cystic Renal Masses Assessed With MRI. AJR: American Journal of Roentgenology, 215(2), 413-419. https://doi.org/10.2214/ajr.19.22740
Urinary Bladder. I. (2010). D. H. Sobin, M. K. Gospodarwicz, & C. Wittekind (red.), TNM Classification of Malignant Tumours (7. utg., s. 262-265). Oxford: Wiley-Blackwell.
Uzosike, A. C., Patel, H. D., Alam, R., Schwen, Z. R., Gupta, M., Gorin, M. A., . . . Pierorazio, P. M. (2018). Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry. Journal of Urology, 199(3), 641-648. https://doi.org/10.1016/j.juro.2017.09.087
Van Poppel, H., Da Pozzo, L., Albrecht, W., Matveev, V., Bono, A., Borkowski, A., . . . Sylvester, R. (2011). A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. European Urology, 59(4), 543-552. https://doi.org/10.1016/j.eururo.2010.12.013
Van Poppel, H., Da Pozzo, L., Albrecht, W., Matveev, V., Bono, A., Borkowski, A., . . . Sylvester, R. (2007). A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. European Urology, 51(6), 1606-1615. https://doi.org/10.1016/j.eururo.2006.11.013
Vasudev, N. S., Wilson, M., Stewart, G. D., Adeyoju, A., Cartledge, J., Kimuli, M., . . . Banks, R. E. (2020). Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open, 10(5), e035938. https://doi.org/10.1136/bmjopen-2019-035938
Volpe, A., Panzarella, T., Rendon, R. A., Haider, M. A., Kondylis, F. I., & Jewett, M. A. (2004). The natural history of incidentally detected small renal masses. Cancer, 100(4), 738-745. https://doi.org/10.1002/cncr.20025
Wersäll, P. J., Blomgren, H., Lax, I., Kälkner, K. M., Linder, C., Lundell, G., . . . Svedman, C. (2005). Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiotherapy and Oncology, 77(1), 88-95. https://doi.org/10.1016/j.radonc.2005.03.022
Whelan, E. A., Mason, R. J., Himmelman, J. G., Matheson, K., & Rendon, R. A. (2019). Extended Duration of Active Surveillance of Small Renal Masses: A Prospective Cohort Study. Journal of Urology, 202(1), 57-61. https://doi.org/10.1097/ju.0000000000000075
WHO Classification of Tumours Editorial Board. (2022). Urinary and Male Genital Tumours (5. utg.). (WHO Classification of Tumours Volume 8). Lyon: IARC.
Wu, J. Y., Mi, Y., Liu, S., Yao, L., Tang, Q., He, Z. S., & Wang, X. Y. (2019). [Evaluating inferior vena cava wall invasion in renal cell carcinoma tumor thrombus with MRI]. Beijing Da Xue Xue Bao Yi Xue Ban, 51(4), 673-677 [på kinesisk]. https://doi.org/10.19723/j.issn.1671-167X.2019.04.013
Xing, M., Kokabi, N., Zhang, D., Ludwig, J. M., & Kim, H. S. (2018). Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study. Radiology, 288(1), 81-90. https://doi.org/10.1148/radiol.2018171407
Yanagisawa, T., Mori, K., Kawada, T., Motlagh, R. S., Mostafaei, H., Quhal, F., . . . Shariat, S. F. (2022). Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. Urologic Oncology, 40(7), 315-330. https://doi.org/10.1016/j.urolonc.2022.04.002
Zhou, M., Mills, A., Noda, C., Ramaswamy, R., & Akinwande, O. (2018). SEER study of ablation versus partial nephrectomy in cT1A renal cell carcinoma. Future Oncology (London, England), 14(17), 1711-1719. https://doi.org/10.2217/fon-2017-0678
Zisman, A., Wieder, J. A., Pantuck, A. J., Chao, D. H., Dorey, F., Said, J. W., . . . Belldegrun, A. S. (2003). Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. Journal of Urology, 169(3), 909-916. https://doi.org/10.1097/01.ju.0000045706.35470.1e